Art Rastinehad, DO, has been selected as a 2026 Castle Connolly Top Doctor, marking his 12th year receiving this honor. Only 7 percent of licensed physicians nationwide are chosen annually for this designation, which is based on peer nominations and a rigorous selection process by Castle Connolly's physician-led research team. Dr. Rastinehad, a professor of urology and radiology, serves as vice chair of urology at Northwell's Lenox Hill Hospital and as Northwell Health System director for prostate cancer.
Dr. Rastinehad's clinical and research focus is on precision prostate cancer diagnosis, MRI-targeted biopsy, focal therapy, image-guided treatment, interventional urology, and prostate artery embolization for benign prostatic hyperplasia (BPH). His approach emphasizes individualized care, coordinating the right evaluation and treatment options for each patient. "My goal is to help men make clear, informed decisions about prostate cancer, enlarged prostate, and urinary symptoms by coordinating the right evaluation and the most appropriate treatment options for each individual patient," said Dr. Rastinehad in a statement. He added that precision prostate care involves matching the right patient to the right diagnosis and treatment, rather than a one-size-fits-all approach.
Dr. Rastinehad's research team has played a key role in advancing image-guided prostate care, including early validation of MR/US fusion biopsy for prostate cancer detection in the United States. His work continues to shape prostate cancer diagnosis, focal therapy planning, minimally invasive treatment, and interventional options for men with BPH. Notably, he was the first dual fellowship-trained urologic oncologist and interventional radiologist, having completed advanced training through the National Institutes of Health, the National Cancer Institute, and Northwell's North Shore University Hospital. This unique combination of expertise allows him to integrate cancer surgery, advanced imaging, and minimally invasive image-guided therapy in one practice.
Key achievements in Dr. Rastinehad's career include being part of the first team to publish a series on prostate artery embolization in 2006, early validation of MR/US fusion biopsy for prostate cancer detection, and serving as principal investigator in the development and clinical use of UroNav/Philips MR/US fusion technology for prostate biopsy and focal therapy planning. He is also a founding executive board member of the Focal Therapy Society and has over 20 years of experience in prostate artery embolization and interventional urology. His practice at the urology department at Lenox Hill Hospital provides advanced prostate care for men with elevated PSA, abnormal prostate MRI, localized prostate cancer, enlarged prostate/BPH, urinary symptoms, and complex treatment decisions.
Castle Connolly Top Doctors are nominated by peer physicians and selected based on criteria including medical education, training, hospital appointments, and disciplinary histories. The list is published at castleconnolly.com and in various print and online partner publications. Doctors cannot pay to be selected for this honor.
